Acetylation Glycation Human serum albumin Lysine Mass spectrometry a b s t r a c t Aspirin (ASA) plays a key role in protecting high risk cardiovascular patients from ischaemic events. The modifications underlying its effects are the results of the trans-acetylation that occurs between ASA and the amino groups made up of lysine and N-terminal residues. ASA's effects have also been demonstrated on several plasma proteins, including human serum albumin (HSA). However, its beneficial effects seem to be lower in diabetic patients, suggesting that protein glycation may impair ASA's acetylation process. Using immunoblotting and mass spectrometry, this study characterized the degree of HSA acetylation mediated by ASA in vitro, as well as the impact of high glucose concentrations. Glycation's influence on HSA acetylation might impair the latter's biological functions, leading to a potential failure of ASA to prevent cardiovascular complications in diabetes. (J.-C. Sanchez).
Introduction
Since its serendipitous discovery and thanks to mid-20th century improvements, aspirin, also known as acetylsalicylic acid (ASA), has become a landmark drug in the history of medicine. ASA is the world's most well-known non-steroidal anti-inflammatory drug; this is due to its pleiotropic effects, either in the ordinary treatment of pain, fever and inflammation, or in clinical practice [1, 2] . Indeed, it is widely used
Abbreviations: ASA, acetyl salicylic acid; HCD, high energy collisional dissociation; HSA, human serum albumin; MS, mass spectrometry. physiological conditions (37 • C, pH 7.4) this reaction is fast and follows a first order kinetic dependent only on the concentration of ASA. After usual therapeutic doses, normal ASA plasma levels range from 0.7 to 2.2 mM, however toxicity can occur when serum concentrations exceed 2.9-3.6 mM and can become fatal beyond 5.4 mM [8] . Several studies have shown the effect of ASA-induced acetylation on different plasma proteins. It increases haemoglobin's affinity to oxygen and consequently reduces the severity of sickle-cell disease [9, 10] . Acetylation of fibrinogen by ASA improves the porosity of the fibrin cloth making it more accessible to plasmin for the fibrinolytic process [11] . ASA also acts on low density lipoproteins, reducing their oxidation level and thus exerting a preventive effect against atherosclerosis [12] . ASA-mediated acetylation has also been detected on human serum albumin (HSA) [13] .
HSA is known to be the most abundant circulating plasma protein, and because it has multifunctional properties it plays key roles in metabolism. It is the main transporter of drugs, hormones, fatty acids and other small metabolites. It regulates oncotic pressure, prevents oxidative damage and has an intrinsic esterase activity. Previous studies showed the involvement of different amino acidic residues in HSA's reactions with low ASA concentrations (0.1-0.5 mM) [14, 15] . It was demonstrated that the acetylation of some of these sites had an impact on HSA's pseudo-esterase catalytic activity, and on its affinity for binding to anionic drugs and metabolites such as bilirubin and prostaglandins. However, HSA's beneficial effects are lower in poorly monitored diabetic patients, via a process termed as 'aspirin resistance'. This can be attributed to insufficient doses of ASA, drug interactions, or the genetic polymorphism of genes involved in thromboxane biosynthesis and turnover [16, 17] . In addition, because high plasma glucose levels encourage protein glycation, they might have a significant effect on aspirin resistance and other metabolic disorders. Glycation is a non-enzymatic post-translational modification, which is boosted under hyperglycaemic conditions (blood glucose concentration ≥ 11 mM). It occurs in a condensation reaction between the carbonyl group in glucose (or any other reducing sugar, such as fructose and derivatives) and a protein's free amino residues (mostly N-terminal and lysine). This process leads to the formation of Amadori compounds which then undergo a series of oxidation, dehydration and fragmentation reactions, finally generating advanced glycation end-products (AGE) [18, 19] . AGEs are associated to long term diabetic complications, such as retinopathy [20, 21] , nephropathy [22] [23] [24] and macroangiopathy [25, 26] ; this is due to the formation of cross-linked structures [27, 28] that alter the structure/function of proteins, their turn-over, and tend to accumulate in specific tissues, impairing their homeostasis [29, 30] . Apart from its clinical relevance as a more rapid indicator for glycaemic monitoringl than glycated haemoglobin (HbA1c), glycated HSA has also been described as having altered functions in diabetes (glycated albumin levels in plasma are considered to indicate the glycaemic state over the last 3 weeks, while HbA1c indicates the glycaemic state over the last 3 months) [31] [32] [33] . Indeed, it was shown that glycation significantly impairs HSA's antioxidant properties [34] and its drug-binding capacity [35] . Furthermore, the alterations to HSA's biophysical properties, induced by glycation, increase its affinity to the receptor for advanced glycation end-products (RAGE) [36] . This leads to several cellular dysfunctions, such as: the intracellular accumulation of lipids in macrophages [37] ; the increase of their inflammatory activity by inducing NF-B [38] ; the secretion of IL-6 by adipocytes [34] ; and the promotion of neuronal apoptosis in the human brain [39] , contributing to the development of Alzheimer's-like diseases.
The potential protective role of ASA in inhibiting the glycation mechanism was previously shown in lens crystallins [40, 41] , collagen [42] , haemoglobin [43] and, most recently, fibrinogen [44] . However, the impact of increased blood glucose concentrations and glycation on ASA-mediated acetylation has been poorly investigated. To date, only Watala et al. have shown the impairment of ASA-induced protein acetylation on platelet membrane proteins in diabetes mellitus, due to an increased level of glycation [45] . Further research is required to determine how high glucose concentrations might hamper the protective action of ASA at the protein level. This study aimed to highlight HSA's acetylation response after incubation, from low to very high ASA concentrations, but also to elucidate which amino acidic residues showed the highest reactivity towards ASA. The study's second aim was to examine the competition between glycation and acetylation in order to demonstrate how these two reactions take place at the protein level. Finally, the characterization of the preferential sites where these two modifications occur was performed using mass spectrometry (MS), and the quantification of glycated and acetylated peptides of HSA was carried out using a label-free approach. This proof-of-concept study lays the foundations for a better understanding of the interaction between the ASA-mediated acetylation and glycation processes on proteins, and gives new insights into their potential antagonist effects in the pathophysiology of diabetes. 
Materials and methods

Chemicals
ASA and glucose incubation of HSA
To test the detection limit of ASA-mediated acetylation using Western blot and LC-MS approaches, five aliquots of 20 L HSA were diluted in phosphate buffer up to 200 L, and subsequently incubated with several ASA concentrations (20, 2, 0.2, 0.02 and 0 mM) for 24 h at 37 • C. To analyze the impact of high glucose concentration on ASA's effects, three aliquots of 20 L HSA were diluted in phosphate buffer to reach a final volume of 200 L, and then incubated: (1) alone for 24 h at 37 • C, (2) with 20 mM ASA for 24 h at 37 • C, and (3) sequentially with 10 mM glucose for 24 h and then 20 mM ASA for 24 h at 37 • C. For the third immunoblot experiment, two groups of three aliquots of 20 L HSA in phosphate buffer (200 L final volume) were incubated with 20 mM ASA and different glucose concentrations (0, 10, and 625 mM) for 24 h at 37 • C; sequential and simultaneous incubations were performed for the first and the second group, respectively. Finally, four conditions (200 L final volume) were created: HSA was incubated alone for 24 h at 37 • C, with 20 mM ASA for 24 h at 37 • C, with 10 mM glucose for 24 h at 37 • C, and with 10 mM glucose followed by an incubation with 20 mM ASA for 24 h at 37 • C. After incubation, protein amounts were determined using the Bradford assay, and BSA was used to create a standard calibration curve.
Western blot analysis of ASA-mediated acetylation
Samples (200 ng) were separated using electrophoresis on an 8%T/2.6%C polyacrylamide gel and protein transfer was carried out for 1 h at 350 mA. Membranes were stained with Amido black [46] to highlight the protein bands, and washed with water to remove the excess of background. Immunoblot was carried out with an anti-human antibody against Nacetyl-lysine in a dilution of 1:5000. The acetylation signal intensity of the immunoblot was normalized relative to the corresponding band stained with Amido black. ECL reagents were used to detect the acetylation signal. Each sample was evaluated with four experimental replicates (n = 4).
Protein purification and Glu-C digestion
After incubation, glucose and salts were removed using Amicon Ultra-0.5 mL, Ultracel ® 3K membrane (Millipore TM ) devices to purify the proteins that were reconstituted in 500 mM TEAB, pH 8.5. Protein concentrations were subsequently measured using the Bradford assay, with BSA as the calibration protein.
Samples were split into two experimental groups in order to analyze the acetylated and glycated peptides separately for each experimental set. For the acetylation study, 100 g of protein were diluted in 400 L of TEAB; while for the glycation study, 1 mg of protein were diluted in 400 L of TEAB, for subsequent protein digestion. For this purpose, disulfide bonds were reduced using 4 L of TCEP to reach a final concentration of 5 mM and the reaction mixture was incubated for 1 h at 60 • C. Cysteine groups were alkylated using 10 L of IAA to reach a final concentration of 20 mM, and incubation was carried out for 30 min at room temperature in dark conditions. Freshly prepared endoproteinase Glu-C (1 mg/mL) was added in a ratio of 1:10 (w/w), and digestion took place for 16 h at 37 • C. For acetylation analysis, digestion mixtures were evaporated under speed vacuum, and directly reconstituted in 5% ACN/0.1% FA for the subsequent desalting procedure. For the glycation analysis, peptide digests were evaporated and reconstituted in mobile phase A (200 mM NH 4 Ac, 50 mM MgCl 2 , pH 8.1) to reach an estimated concentration of 16 mg/mL, for the fractionation of glycated peptides.
Enrichment of glycated peptides by boronate affinity chromatography
Reconstituted peptides were enriched using boronate affinity chromatography-by interaction between cis-diol groups of glycated peptides, present at low concentration, and boronate groups of the stationary phase, as previously described [47, 48] . For this purpose, a 50 L room temperature sample was injected in a Waters 600E HPLC system equipped with a TSK-Gel boronate affinity column from Tosoh Bioscience (7.5 cm length × 7.5 mm inner diameter, i.d., 10 m particle size). A chromatographic method based on a gradient with two isocratic steps was used to separate non-glycated from glycated fractions.
Step 1 was a 0-10 min, 100% mobile phase A (200 mM ammonium acetate, 50 mM magnesium chloride, pH 8.1) for retention of glycated peptides by esterification of the 1,2 cis-diol group of glucose moieties and the hydroxyl groups of boronate ligands under alkaline conditions. Non-glycated peptides were eluted. Step 2 was a 10-20 min, 100% mobile phase B (100 mM acetic acid) for the elution of glycated peptides under acidic conditions; 20-30 min, 100% mobile phase A to bring the column back to the initial equilibrium conditions. The glycated fraction was collected for subsequent evaporation and reconstitution in 5% ACN/0.1% FA, for the ensuing desalting and concentration.
LC-MS/MS detection of acetylated and glycated peptides
Samples from acetylated and glycated data sets were desalted and pre-concentrated using a MacroSpin Column TM C 18 (Harvard Apparatus), according to the manufacturer's protocol. Peptides were eluted in 400 L of 50% ACN/0.1% FA and then evaporated to dryness before reconstitution in 5% ACN/0.1% FA, prior to LC-MS/MS analysis. Peptide digests were analyzed using electrospray ionization in positive ion mode (1.6 kV ionization voltage), on an Orbitrap hybrid linear ion trap (Thermo Fisher). Nanoflow was carried out using a Waters NanoAquity HPLC system consisting of a pre-column (100 m inner diameter and 18 mm in length) packed with C 18 resin, where peptides are initially loaded and trapped at a flow rate of 3 L/min in water/ACN (95/5, v/v) with 0.1% FA. After retention, peptides were eluted using an ACN gradient developed in an analytical column packed with C 18 resin, at the flow rate of 200 nL/min with mobile phase A (water, 0.1% FA) and B (ACN, 0.1% FA). The mass spectrometer was operated in data-dependent MS/MS mode with a precursor-ion scan range of 400-1600 m/z and a resolving power of 60,000. Each sample in both data sets was analyzed four times using high energy collisional dissociation (HCD) as the activation mode. The 3 most abundant ions detected from the MS survey scan were selected as precursor ions for fragmentation (normalized collision energy, 40%), followed by Orbitrap detection with a resolving power of 7500 with a dynamic exclusion of 45 s, to minimize repeated analysis of the same precursor ion. All analyses were carried out using four replicate injections.
Data analysis
After data-dependent acquisition, peak lists were generated from raw data using EasyProtConv v1.5 software, and the resulting data files were searched for matches against the UniProtKB/Swiss-Prot database (Release June 13, 2012, 647,369 entries) using the EasyProt v2.2 (build 612) tool [49] . Because this study analyzed human albumin, we selected Homo sapiens taxonomy for the protein search. The high resolution of the acquired data allowed the scoring model to use an accuracy of 6 ppm on fragments and 10 ppm on precursors. Common amino acid modifications detected were carbamidomethylation of cysteine residues (57.0215 Da) and oxidized methionine (15.9949 Da); these were set as fixed and variable modifications, respectively. Additional variable modifications, for acetylation and glycation, were selected on lysine residues and N-terminal positions. For the analysis of acetylated peptides, the selection of acetylation-induced modification was based on the peptide attachments of the acetyl group (42.0100 Da), while for the selection of glycated peptides, the mass shift was built on the attachment of the entire glucose molecule (162.0523 Da). The number of modifications per peptide was set to a maximum of 2 in order to reduce the search space of all possible combinations of variable modifications. Endoproteinase Glu-C was selected as the cleavage enzyme, with three potential missed cleavages allowed. The minimum peptide length was 8, with a minimum peptide z-score of 4. Four analytical injections per sample, each analyzed in independently, provided replicate data values. The peak list files obtained for each technical replicate were merged and submitted for the database search. For the significance of peptide identification we used a false-discovery rate of 5%. Peptides were considered as identified if they were present 2 times out of 4, but the majority of them were found at least 3 times out of 4.
Peptide quantification
Label-free quantitation of glycated and acetylated peptides from HSA was done using Nonlinear Dynamics' Progenesis software. This relies on the accurate alignment of m/z and Rt features for every chromatographic run in each group. A global peak list file, containing all the features detected, was used to query the database as above and, from the identification results, a pepXML file was exported to Progenesis. All the identified peptides were then matched using their relative features. Quantitation is carried out using the normalized abundance for each peak corresponding to features and comparing it to the same peak for all the conditions analyzed. The normalization of peptide abundance was performed automatically by Progenesis. Briefly, the software selects one technical replicate as a reference; after calculating the raw intensities for each peptide on each replicate, it determines the ratio between the replicate being normalized and the reference replicate. Then, a distribution of log (ratios) is calculated and a global scaling factor (the anti-log of the average of the log (ratios)) is determined. The raw intensities for each peptide among different replicates are multiplied by the global scaling factor.
Results and discussion
For several decades, ASA and ASA derivatives have been shown to have a significant biological and clinical effects. One of these effects relies on ASA's protective action against protein glycation, and has been clearly documented using in vivo and in vitro models [50, 51] . Indeed, modifications in both environments occur at the same functional groups on proteins, but it is not clear whether acetylation and glycation share the same target sites, and are thus in direct competition, or whether they target different sites and thus induce potential conformational changes in protein structures. This study's purpose was to characterize the effects of glucose on ASA-mediated acetylation using an in vitro model based on HSA. Only one previous study demonstrated an association between glycation and ASA on HSA [50] , but it reported no particular information regarding the exact sites at which these modifications were involved. The current study established a relationship between ASA-induced acetylation and protein glycation, starting from the analysis of the preferential acetylated sites on HSA and moving on to the influence that high glucose concentration might have on the acetylation process, and vice versa, through label-free quantification.
Qualitative and quantitative analysis of acetylation and glycation on HSA
The present study used a proteomic workflow for the analysis of acetylation and glycation on HSA; this comprised both immunoblot and tandem mass spectrometry (MS) approaches. These gave qualitative and quantitative estimations of the extent of these two modifications at the protein level ( Fig. 1) . Following exposure to ASA, and after glucose and ASA coincubation, the acetylation level of native HSA was first measured by a Western blot test using an anti-acetyl lysine antibody, as previously mentioned. The immunoreaction signal was normalized on the corresponding Amido-black stained band on the same blot. Intensity values were measured using TotalLab Quant software. For the MS analysis, a new condition was created in which HSA was incubated with glucose alone, in addition to the other 3 used for immunoblot. Samples were purified from glucose and ASA, and then digested with endoproteinase Glu-C. The choice of this enzyme is supported by the fact that acetyl groups and glucose attachments are selective for lysine residues, and for this reason the trypsin digestion pattern can be affected by an increase of missed cleavage sites. The influence of these two modifications is less dramatic for endoproteinase Glu-C, and the identification of missed cleavage sites might be considerably reduced. After digestion, two distinct data sets were created: one for acetylated peptide analysis and one for glycated peptide analysis.
Concerning mass spectrometry, electron transfer dissociation (ETD) [52] and collision induced dissociation (CID) in neutral loss scanning and multistage activation [53] with an ion trap mass analyzer have successfully proved their efficiency in data-dependent methods for the identification of glycated peptides. Nevertheless, coupling HCD fragmentation with Orbitrap detection also allowed the obtainment of high quality MS/MS spectra, which enhanced the identification of acetylated and glycated peptides. HCD employs higher dissociation energies by using nitrogen as the collision gas; this results in more efficient fragmentation than with the helium-based dissociation occurring in CID. Moreover, HCD activation mode is faster than with CID, leading to high vibrational energies before dissociation of the molecular ion. This is fundamental for the analysis of modified peptides in which functional groups are retained on the peptide backbone during the fragmentation process [54] . The present study used HCD fragmentation, and two data files were created for the subsequent identification and quantification by label-free quantification of acetylated and glycated peptides, with localization of the target sites where these two modifications occurs.
Analysis of the detection limit of ASA-mediated acetylation on HSA
Acetylation levels of HSA exposed to decreasing concentrations of ASA were analyzed. Immunoblot analysis clearly revealed a strong acetylation reaction when HSA was incubated with 20 mM ASA; this decreased considerably (−85%) with 2 mM ASA incubation. No immunoreactivity was detected after 0.2 and 0.02 mM ASA exposure (Fig. 2) , confirming the inability of this analytical technique to detect low acetylation levels on proteins. On the other hand, the high sensitivity of MS analysis allowed the obtainment of more informative results. The degree of acetylation was directly proportional to the ASA concentration used (from 20 to 0.02 mM); Fig. 3A and B shows the decrease in the total number of unique acetylated peptides and sites, respectively. It should be noted that the higher number of acetylated sites, compared to the number of acetylated peptides can be explained by the low digestive efficiency of Glu-C; because it produces longer peptides than those generated by trypsin digestion, this increases the number of sites modified per peptide sequence. However, when HSA was incubated with 0.02 mM ASA, the reverse situation was found, with a total of 7 acetylated peptides and 6 acetylated sites. This can be explained by the presence of two unique peptides, which modify the same Lys residue, but that differ in the presence of one missed cleavage site. The detailed list of acetylated peptides and their corresponding identified sites are shown in Table 1 . MS analysis enabled the characterization of acetylation even when HSA was exposed to low doses of ASA (0.2 and 0.02 mM), levels at which detection using immunoblot was impossible. Indeed, identifying sites that showed a high tendency to be acetylated by ASA was an important aspect of analysis. HSA's reaction with 0.02 mM ASA yielded 6 modified sites: Lys 51, 64, 93, 444, 545 and Arg 81. This is the first time that the identity of these sites has been reported at such a low ASA concentration. Furthermore, this method revealed native acetylation, which allowed the identification of Lys 93 residue. The high tendency of these sites to be acetylated by ASA might be attributable to their location at the protein surface, or to the surrounding basic residues that impede their protonation. With 0.2 mM ASA, the number of modified sites increased and it was possible to detect the two known preferential acetylation sites in Lys 199 and 519, as previously reported [15, 55] . Differently from Lys 519, which is an external site, Lys 199 is present in an internal pocket of the protein, and owes its high reactivity to the low pK a of its side chain. A further increase of acetylated residues was found after incubation with 2 mM and 20 mM ASA, but this would be less likely to occur in vivo since these two concentrations are much higher than ASA's therapeutic range (0.1-0.5 mM) [14] .
Glycation effects on HSA's ASA-mediated acetylation
This study investigated the influence of glycation on HSA's acetylation as induced by ASA. The degree of acetylation of native HSA was compared with those of HSA after 24 h ASA incubation, both with and without exposure to glucose. The immunoblot showed a visible difference in the reactions under the different conditions tested. The acetylation signal in HSA incubated with ASA alone (Fig. 4, lane 2) was clearly lower than the signal in HSA incubated with ASA and glucose (Fig. 4,  lane 3) , and no signal was detected in native HSA (Fig. 4, lane  1) . These results convincingly showed that glycation significantly affects protein acetylation when HSA is incubated with 10 mM of glucose and 20 mM ASA; this suggested that high glucose concentrations had a direct impact, even when the ASA concentration was far beyond the normal therapeutic level in blood. Indeed, the concentration of ASA used in this study was higher than the therapeutic plasma range precisely to enhance the acetylation process and to reach a quasisaturated state of albumin. Because the physiological plasma levels of ASA are around 0.2-1.5 mM, we assumed that by using
Fig. 5 -Extracted ion chromatograms in MS2 of immonium ions calculated for (A) acetylated, and (B) glycated Lys in HSA after 20 mM ASA and 10 mM glucose incubation, respectively. Tandem mass spectra highlighting the presence of (C) acetylated immonium ions, and (D) glycated immonium ions.
an ASA concentration 20 times higher, the level of occupancy of the lysine sites would be near to completeness; any variation of the degree of acetylation, therefore, would be due to the glucose effect. Moreover, another of the study's aims was to characterize the higher number of preferential acetylation sites on HSA.
The degree to which acetylation is inhibited is dependent on the extent of glycation. Indeed, as the glucose -208 197,199 195,197,199 195,197,199 195,197,199 concentration increased, a significant decrease of the acetylation immunoreaction signal was detected across the different conditions tested (Supplementary data Fig. S1 ). The level of acetylation was significantly lower after incubation with 625 mM glucose, showing that inhibition of the ASA reaction is directly correlated to the glucose concentration.
Detection of modified immonium ions to confirm the presence of modified peptides
The high fragmentation efficiency of HCD, coupled with its high resolution, high accuracy and the no low mass cut-off of Orbitrap detection, revealed the presence of immonium ions that were clearly visualized in the low mass range, confirming peptide identification. These immonium ions made it possible to pinpoint the presence of modified amino acids, such as acetylated and glycated lysine residues. The most frequent Lys immonium ion provided a signal at 84.081 Da, which shifted to 126.091 Da after acetyl group attachment and to 246.134 Da after glucose attachment. However, in the latter case, the typical neutral losses detected in glycated peptides should be taken into account, such as the loss of three water molecules (−54.031 Da), and the intramolecular rearrangement of the glucose moiety (−84.042 Da), which generated signals at 192.102 and 162.091 Da, respectively. Because of the selectivity of these ions, acetylated and glycated peptides can be localized by extracting ion chromatograms in MS/MS ( Fig. 5A and  B) . These were monitored at 126.09 m/z for the acetyl-lysine immonium ion (Fig. 5C ) and at 162.09 and 192.10 m/z for the furyliumand pyrylium-lysine immonium ions, respectively ( Fig. 5D ). These fingerprints provided additional evidence for the assignment of acetylated and glycated peptides, respectively [47] . Due to the high accuracy of the instrument used, it was possible to precisely select the m/z of either the lysine acetylated or glycated immonium ion which defined the presence of a modified residue in the MS/MS spectrum.
Quantitation of acetylated and glycated peptides on HSA
The application of this protocol provided profiles of the acetylated and glycated peptides including their modification sites on HSA. From a qualitative point of view, the total number of unique acetylated peptides was considered for each condition. Only one unique acetylated peptide was found in native HSA and in HSA after glucose exposure. However, this number increased to 12 peptides after simultaneous incubation with glucose and ASA, and up to 18 after ASA incubation alone ( Table 2 ). It was observed that most of the sequences of acetylated peptides contained at least two modified sites; this was ascribed to the low efficiency of Glu-C, as mentioned above. On the glycation side, 17, 21, 22 and 18 unique glycated peptides were found in native HSA, HSA after incubation with 20 mM ASA, HSA after incubation with 10 mM glucose, and HSA after simultaneous glucose and ASA incubation, respectively ( Table 3 ). The level of glycation and acetylation on HSA was measured using label-free quantitation. This method is based on the precise alignment of chromatographic peaks derived from the Rt and m/z features of each peptide identified. Raw LC-MS data were imported into Nonlinear Dynamics' Progenesis analysis software where the feature extraction and alignment processes take place across all the replicates for each condition. As previously explained, the identification results derived from all the peak lists were associated to their respective features and the peak totals for each peptide was calculated. Using this approach, 18, 18, 21 and 20 unique glycated peptides were quantified for native HSA, HSA after incubation with 20 mM ASA, HSA after incubation with 10 mM glucose, and HSA after simultaneous incubation of 10 mM glucose and 20 mM ASA, respectively. Taking all the glycated peptide totals measured in each condition, a significant decrease was observed between when ASA and glucose are incubated together and when glucose was incubated alone (Fig. 6A ). Across all 4 conditions, 11 glycated peptides were found to be in common in all 4 conditions and all of them showed a significant decrease in glycation levels when ASA was incubated with glucose. Fig. 6B shows data from a representative glycated peptide (TFTFHADICTLSEKE) of HSA in order to highlight ASA's protective effects against glycation. Fig. 6C represents the total abundance of the acetylated peptides. No acetylated peptides were quantified for either native HSA or HSA with 10 mM glucose. However, the peak abundance of 12 and 9 unique acetylated peptides was measured for HSA after 20 mM ASA incubation and after glucose and ASA co-incubation, respectively. This lends further evidence to the theory of mutual competition between these two uncontrolled post-translational modifications. Across both conditions in which the acetylation level was measured, only 5 quantified peptides were found in common. Fig. 6D shows HSA's TFTFHA-DICTLSEKE peptide (also found to be glycated) which better illustrates the blocking effect of glucose on ASA-mediated acetylation at the protein level. Taking into account the number of modified peptides (from the acetylation and glycation data sets), and the unmodified form of the same peptides, the extents of acetylation and glycation in HSA were calculated at 42% and 13%, respectively. Taken together these results demonstrate a relevant interaction between these two modifications: from one side ASA tends to reduce the glycation level through the acetylation of preferential sites, and on the other, glucose hampers the ASA effect by decreasing the acetylation content of the protein, as also confirmed by Western blot. These results represent the first proof of the interplay between ASA and glucose at the protein level, suggesting a potential competition effect induced by glucose reducing the content of acetylation, and on the other side, induced by ASA, protecting the protein from further glycation. 
Localization of glycation and acetylation sites on HSA
The precise sites of glycation and acetylation modifications on HSA were analyzed in order to characterize the potential amino acid targets. A unique acetylated site (Lys 93) was found both in native HSA and HSA after glucose incubation; while HSA after ASA incubation identified 26 unique acetylated sites, and HSA incubated with glucose and ASA identified 15 unique acetylated sites (Table 2) . Lys 199 and Lys 519 were found to be common to both types of incubations and had been reported as preferential acetylation sites in a recent study [15] .
Glycation analysis yielded 15 unique glycated sites endogenous in native HSA, of which Lys 525 had been previously reported as a highly reactive glycation site [56, 57] . In addition, glycation on native HSA was also detected at Lys 64, 73, 93, 199, 233, 262, 372, 436, 475, 519 and 524. Most of these residues were located at the protein surface exposed to the solvent or close to basic amino acids in the tertiary structure, thus making them more likely to the attach to glucose. The number of glycated sites increased to 27 after glucose incubation and to 21 when glucose and ASA were co-incubated ( Table 2 ). Most of the sites identified were consistent with those reported by previous works in which high glycation levels were analyzed [19, 37] . To assess which sites were shared by acetylation and glycation modifications, the data sets of acetylated and glycated sites obtained from the sequential incubation of glucose and ASA were compared. Eight sites (Lys 51, 64, 73, 93, 199, 519, 525 and 574) were found to be in common ( Fig. 7A ). Of these, Lys 93 was detected as a native HSA acetylated and glycated site, Lys 525 was previously shown to be a major glycation site, and residues Lys 199 and 519 were found to be highly responsive to ASA. Fig. 7B shows the crystal structure of HSA, with its solvent accessible surface area, and the 8 modified lysines are represented by coloured sticks (Fig. 7B ). With the exception of Lys 199, which is present in an internal pocket, the spatial distribution of the other sites' modified residues shows them to be on surfaces of the protein, readily accessible to the solvent, thus explaining their high tendency to acetylation and glycation. Surface solvent accessibility is defined as the surface traced by the centre of an ideal sphere with a radius of 1.4Å as it rolls across the protein's van der Walls surface, and it is calculated using the rolling ball algorithm present in PyMOL v1.6 software.
Looking at the MS/MS spectrum for each of these sites, it was possible to highlight the peptide backbone, with identification of its y and b ions, together with the relative mass displacements due to the modifications. As an example, Fig.  S2A and B in the Supplementary data shows the MS/MS spectrum for the acetylated and glycated forms of HSA's TFTFHADICTLSEKE peptide at Lys 519. The elucidation of new molecular targets for both ASA-induced acetylation and glycation could have important consequences on the biological functions of HSA. The presence of residues modified by an acetyl group or a glucose attachment could induce conformational changes of different protein regions, thus influencing HSA's affinity for binding to metabolites, drugs and fatty acids. Indeed, most of these interactions occur in pockets on the protein's surface, which is where this study identified the majority of acetylated and glycated sites. Furthermore, many other molecular processes could be affected by this interplay between acetylation and glycation, such as HSA's aforementioned antioxidant activity or its pseudo-esterase activity. Interestingly, one of the residues this study found to be acetylated (Arg 472) is very close to Tyr 411 (11.67Å) (data not shown), HSA's central site of the esterase activity [58] ; it is also close to Lys 199, which was seen to be both acetylated and glycated. Thus, depending on the extent to which these two non-enzymatic, post-translational modifications occur, and their competition for the same chemical groups, their roles in protein structures and functions could be different, leading to significantly altered protein responses.
Conclusion
The present work aimed to evaluate the extent of HSA acetylation using a range of ASA doses, and to demonstrate the influence of glycation on the acetylation process. A dosedependent increase in the number of acetylated peptides and sites was observed after in vitro incubation with ASA. The significant impact that high glucose levels have on limiting protein acetylation was also demonstrated, and the favoured acetylation and glycation sites on HSA were characterized.
Finally, a label-free quantitation was performed to better confirm the interplay and the reciprocal competition between glycation and ASA acetylation. Our pilot study has laid down the foundations for a more extensive future qualitative and quantitative analysis of acetylated and glycated proteins in clinical blood samples. This will help better evaluate whether these phenomena occur in vivo and to define their relevance to the pathophysiological mechanisms related to diabetes.
